Integrated Diagnostics (IDHC) H1 2025 earnings summary

Executive summary

• Revenue grew 42% year-over-year to EGP 3.54 billion in H1 2025, driven by a 10% increase in test volumes and a 29% rise in average revenue per test.

• Gross profit rose 61% to EGP 1.49 billion, with margin improving to 42% from 37% last year.

• Adjusted EBITDA increased 78% to EGP 1.19 billion, with margin up to 34% from 27% in H1 2024.

• Net profit reached EGP 571 million, up 19% year-over-year; normalized net profit (excluding FX gains) more than doubled to EGP 575 million.

• Board approved a USD 10 million cash dividend (USD 0.017/share) for FY 2024, reflecting robust liquidity and performance.

Financial highlights

• Consolidated revenue reached EGP 3.54 billion, up 42% year-over-year for H1 2025.

• Gross profit margin expanded to 42% (from 37%); adjusted EBITDA margin rose to 34% (from 27%).

• Adjusted net profit margin rose to 16% in H1 2025 (from 7%); effective tax rate increased to 37%.

• Cash balance stood at EGP 1.7 billion as of June 2025.

• Earnings per share reached EGP 0.95, up from EGP 0.88 in H1 2024.

Outlook and guidance

• Full-year 2025 revenue growth expected at or above 30%.

• EBITDA margin guidance for FY 2025 is above 30%, with continued cost control to offset inflation.

• Home service revenue targeted to grow from 20% to potentially 40% of total revenue.

• Focus on price optimization, volume growth, and cost control in Egypt; ramp-up in Saudi Arabia with three new branches planned by year-end.

• Nigeria expected to sustain profitability as inflation stabilizes and volumes recover.